advisorsecurities master

AVTXAvalo Therapeutics, Inc. Common Stock

CSNasdaq (XNAS)·USD

Identity

Security key
12129
Ticker
AVTX
Type
CSCommon Stock
Exchange
Nasdaq(XNAS)
Venue group
NASDAQ
Operating MIC
XNAS
Market
stocks
Locale
us
Currency
USD
Listed
2015-11-13
Round lot
100
Active
Yes
Last seen in a load
2026-08-14 20:49
Vendor updated
2026-08-13 06:09
Ticker root / suffix
AVTX

Detail

Enriched 2026-08-14 20:47

Market cap
$1,048,466,284.95
Shares outstanding (class)
53,629,989
Shares outstanding (weighted)
53,629,989
SIC
2834 PHARMACEUTICAL PREPARATIONS
Employees
33
Location
WAYNE, PA
Description

Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.

Market cap and share counts drift.

Funds holding this security

Identifiers

Classification

Fund data